Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline

- P-tau217 in blood showed promise as additional biomarker of efficacy - Donanemab treatment led to 24% lowering of P-tau217 from baseline INDIANAPOLIS , July 29, 2021 /PRNewswire/ -- Today at the Alzheimer's Association International Conference © (AAIC © 2021), Eli Lilly and Company (NYSE: LLY)